Advertisement

Topics

Companies Related to "Interleukin18 IL18 Inhibitors Pipeline Insights 2017 Updated 30052017" [Most Relevant Company Matches] RSS

11:07 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "Interleukin18 IL18 Inhibitors Pipeline Insights 2017 Updated 30052017" found in our extensive corporate database of over 50,000 company records.

Showing "Interleukin18 IL18 Inhibitors Pipeline Insights 2017 Updated 30052017" Companies 1–25 of 1,500+

Relevant

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...


KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer...


Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:An Osteoporosis programme based on cathepsin K inhibitors, A Psoriasis programme based on a cathepsin S inhibit...

Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

ILEX Oncology

Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ILEX is also advancing a robust pipeline of oncology product candidates. The pipeline comprises multiple technologies at all stages of clinical development, including a monoclonal antibody, apoptosis-inducing agents, cytotoxic compounds with novel mechanisms o...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

Capitol Insights

Capitol Insights helps organizations develop and implement comprehensive public relations and government affairs programs to educate the public, motivate people and shape public policy.Capitol Insights helps clients understand how policy may move in the future because of changes in public opinion, political pressure and legal interpretation. Helping organizations make better decisions and build st...

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

QIAGEN GmbH

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Isarna Therapeutics GmbH

Isarna Therapeutics has an unmatched commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. Isarna Therapeutics are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.  The role of tgf-beta in cancer The cytokine human transforming growth ...

Transcend Insights and Humana Inc.

Transcend Insights, the population health technology company of Humana Inc. (NYSE: HUM), provides solutions that rise above data silos and connect care teams with the insights they need to succeed in a value-based care world. By leveraging its leading-edge approach to data aggregation, interoperability and analytics, Transcend Insights provides health syst...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

QIAGEN N.V.

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these...

Valify, Inc.

Valify, named as a Gartner “Cool Vendor” for Supply Chain Execution Technologies in 2017, is a purchased services technology solution that enables health care organizations to quickly identify spend, benchmark performance, and monitor savings in over 1,200 categories. With proprietary benchmarking analysis, market share insights, and customizable...

Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

Viamet Pharmaceuticals, Inc.

Viamet discovers and develops novel inhibitors of key metalloenzymes via an innovative and proprietary metal-binding approach, the Metallophile™ Technology. Viamet’s disruptive Metallophile™ Technology is based on world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to identify metalloenzyme targets with high therape...

Hallmark Insights

Headquartered in Minneapolis, Hallmark Insights, a wholly owned subsidiary of Hallmark Cards, Inc., provides meaningful, memorable and measurable incentive solutions for health and wellness programs, employee reward and recognition programs, sales and dealer programs and consumer programs. Hallmark Insights solutions combine the convenience of Internet shopping with easy-to-use service to promptly...

Amura Therapeutics Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™: An Osteoporosis programme based on cathepsin K inhibitors A Psoriasis programme based on a cathepsin S inhibit...

inVibe

inVibe is transforming how healthcare organizations get insights by delivering structured, qualitative insights on demand. inVibe has created the industry’s first and only fully-automated mobile research platform that is capable of reaching millions of patients and doctors across hundreds of conditions and specialties and capturing their voice. inVibe...

Forbes Insights

Forbes Insights (www.forbes.com/forbesinsights) is the strategic research practice of Forbes Media, publisher of Forbes magazine and Forbes.com. Taking advantage of a proprietary database of senior-level executives in the Forbes community, Forbes Insights’ research covers a wide range of vital business issues, including: talent management; marketing; ...

Medscape, LLC

Medscape is organized by medical specialty, with each supported specialty having its own customized Web site. Specialty content is evaluated, created, and presented under the guidance of a Medscape program director and a medical professional advisory board.Most specialty sites are organized consistently so you'll know where to find your favorite features as you move from specialty to specialty. Ea...

Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(ga...

Five Prime Therapeutics

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has developed a library of more than 5,600 human extracellular proteins. Five Prime screens this comprehensive library with its proprietary high-throughput protein screening technologies to identify new targets f...


More From BioPortfolio on "Interleukin18 IL18 Inhibitors Pipeline Insights 2017 Updated 30052017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks